TR200000913T2 - Tıbbi maddeler - Google Patents

Tıbbi maddeler

Info

Publication number
TR200000913T2
TR200000913T2 TR2000/00913T TR200000913T TR200000913T2 TR 200000913 T2 TR200000913 T2 TR 200000913T2 TR 2000/00913 T TR2000/00913 T TR 2000/00913T TR 200000913 T TR200000913 T TR 200000913T TR 200000913 T2 TR200000913 T2 TR 200000913T2
Authority
TR
Turkey
Prior art keywords
medical substances
substances
medical
treatment
relates
Prior art date
Application number
TR2000/00913T
Other languages
English (en)
Inventor
Wayne Mangel Allen
Ruth Northctt Allison
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10820099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200000913(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of TR200000913T2 publication Critical patent/TR200000913T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Bu bulus kabiz olmayan disi IBS hastalarinin tedavisinde 5-HT3 resepyörü antagonistlerinin kullanimina iliskindir.
TR2000/00913T 1997-10-07 1998-10-05 Tıbbi maddeler TR200000913T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9721139.5A GB9721139D0 (en) 1997-10-07 1997-10-07 Medicaments

Publications (1)

Publication Number Publication Date
TR200000913T2 true TR200000913T2 (tr) 2001-01-22

Family

ID=10820099

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00913T TR200000913T2 (tr) 1997-10-07 1998-10-05 Tıbbi maddeler

Country Status (36)

Country Link
US (3) US6284770B1 (tr)
EP (1) EP1021174A2 (tr)
JP (1) JP2001518495A (tr)
KR (1) KR20010015707A (tr)
CN (1) CN1281357A (tr)
AP (1) AP2000001785A0 (tr)
AR (1) AR017296A1 (tr)
AU (1) AU750818B2 (tr)
BR (1) BR9812886A (tr)
CA (1) CA2305751A1 (tr)
CO (1) CO5011096A1 (tr)
DZ (1) DZ2618A1 (tr)
EA (1) EA003184B1 (tr)
EE (1) EE200000214A (tr)
GB (1) GB9721139D0 (tr)
GT (1) GT199800157A (tr)
HN (1) HN1998000155A (tr)
HR (1) HRP20000198A2 (tr)
HU (1) HUP0003750A3 (tr)
ID (1) ID23874A (tr)
IL (1) IL135398A0 (tr)
IS (1) IS5425A (tr)
MA (1) MA26549A1 (tr)
NO (1) NO20001776L (tr)
NZ (1) NZ503698A (tr)
PA (1) PA8461101A1 (tr)
PE (1) PE120299A1 (tr)
PL (1) PL340337A1 (tr)
SK (1) SK4862000A3 (tr)
SV (1) SV1998000122A (tr)
TN (1) TNSN98179A1 (tr)
TR (1) TR200000913T2 (tr)
UY (1) UY25200A1 (tr)
WO (1) WO1999017755A2 (tr)
YU (1) YU20600A (tr)
ZA (1) ZA989061B (tr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
US6136807A (en) * 1998-11-10 2000-10-24 3M Innovative Properties Company Composition for the transdermal delivery of lerisetron
EP1090638A1 (en) * 1999-10-08 2001-04-11 Sanofi-Synthelabo Use of (R)-zacopride or a salt thereof for the manufacture of a medicament for the treatment of sleep apnea
TWI263496B (en) * 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
DE10015783C2 (de) * 2000-03-30 2003-12-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Lerisetron und seine Verwendung
WO2001087305A2 (en) * 2000-05-18 2001-11-22 Glaxo Group Limited Method for treating functional dyspepsia using alosetron
US6566369B2 (en) 2000-07-26 2003-05-20 Solvay Pharmaceuticals Gmbh Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
AR028970A1 (es) * 2000-07-26 2003-05-28 Solvay Pharm Gmbh USO DE CILANSETRON O DE SUS SALES POR ADICIoN DE A CIDOS Y/O SOLVATOS FARMACOLoGICAMENTE COMPATIBLES PARA LA OBTENCIoN DE PREPARADOS FARMACEUTICOS PARA EL TRATAMIENTO Y/O LA PROFILAXIS DEL SíNDROME DEL INTESTINO IRRITABLE
AU2001288564A1 (en) * 2000-09-06 2002-03-22 Glaxo Group Limited 5-hydroxytryptamine receptor gene polymorphisms and response to treatment
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
EP1395289B1 (en) * 2001-06-07 2010-12-15 Christine Dr. Sang Treatment of neuropathic pain with a n-methyl-d-aspartate (nmda) receptor antagonists
US7045549B2 (en) * 2001-11-08 2006-05-16 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of symptoms associated with irritable bowel syndrome
ES2281646T3 (es) * 2002-01-18 2007-10-01 Aryx Therapeutics Antagonistas del receptor 5-ht3 y procedimientos de utilizacion.
CN1668307A (zh) * 2002-07-10 2005-09-14 阿瑞科诺沃治疗有限公司 治疗功能性肠紊乱的4－(2－氟苯基)－6－甲基－2－(1－哌嗪基)噻吩并[2,3－d]嘧啶
DE10232750A1 (de) * 2002-07-18 2004-02-05 Basf Ag Verfahren zur Herstellung von macrocyclischen Ketonen durch Dieckmann-Kondensation in der Gasphase
JP4399862B2 (ja) * 2002-08-09 2010-01-20 味の素株式会社 腸疾患および内臓痛の治療薬
US20030187017A1 (en) * 2002-11-14 2003-10-02 Mangel Allen Wayne Method for treating functional dyspepsia
KR20050111318A (ko) * 2003-01-13 2005-11-24 다이노젠 파마세우티컬스, 인코포레이티드 기능성 장 질환을 치료하는 방법
ES2285407T3 (es) * 2003-01-13 2007-11-16 Dynogen Pharmaceuticals Inc. Metodo para el tratamiento de nauseas, vomitos, arcadas o cualquiera de sus combinaciones.
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
ZA200409537B (en) * 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
EP1594493A2 (en) * 2003-12-16 2005-11-16 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
CA2516433C (en) * 2004-01-30 2009-06-02 Astellas Pharma Inc. Ramosetron hydrochloride for diarrhea-predominant irritable bowel syndrome
JP3763360B2 (ja) * 2004-01-30 2006-04-05 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
US7358270B2 (en) 2004-01-30 2008-04-15 Astellas Pharma Inc. Treating agent for irritable bowel syndrome
WO2005073220A1 (ja) * 2004-01-30 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. 下痢型過敏性腸症候群治療剤
US20080008741A1 (en) * 2004-02-03 2008-01-10 Eyal Raz Methods of Treating Irritable Bowel Syndrome
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
WO2005082887A1 (ja) 2004-02-26 2005-09-09 Aska Pharmaceutical Co., Ltd. ピリミジン誘導体
JP2006028028A (ja) * 2004-07-12 2006-02-02 Teikoku Medix Kk 経口医薬組成物
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
EP1902053B1 (en) * 2005-06-07 2011-01-12 Theravance, Inc. Benzoimidazolone-carboxamide compounds as 5-ht4 receptor agonists
WO2007000046A1 (en) * 2005-06-27 2007-01-04 Holburn Biomedical Corporation Methods for diagnosing functional bowel disease
JP4632204B2 (ja) * 2005-09-21 2011-02-16 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
JP5157892B2 (ja) * 2006-02-20 2013-03-06 アステラス製薬株式会社 アミド誘導体またはその塩
WO2009053754A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
WO2009053732A1 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel salt
WO2009053733A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
WO2009053750A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline and amorphous forms
US8734867B2 (en) * 2007-12-28 2014-05-27 Liveleaf, Inc. Antibacterial having an extract of pomegranate combined with hydrogen peroxide
ES2791485T3 (es) 2009-03-04 2020-11-04 Liveleaf Inc Método y material para complejación en el sitio activo de moléculas biológicas
ES2639364T3 (es) 2009-04-29 2017-10-26 Ganeden Biotech, Inc. Formulación de membrana celular bacteriana
JP5741433B2 (ja) * 2009-06-30 2015-07-01 アステラス製薬株式会社 緩解期の炎症性腸疾患患者における排便異常治療剤
JP5938886B2 (ja) * 2010-12-14 2016-06-22 アステラス製薬株式会社 活動期の炎症性腸疾患患者における排便異常治療剤
US9192635B2 (en) 2011-06-24 2015-11-24 Liveleaf, Inc. Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide
US8722040B2 (en) 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
US20120329736A1 (en) * 2011-06-24 2012-12-27 Huang Alexander L Treatment for gastrointestinal disorders using a selective, site-activated binding system
JP2014530249A (ja) * 2011-10-18 2014-11-17 ヘルシン ヘルスケア ソシエテ アノニム ネツピタントおよびパロノセトロンの治療学的組合せ
CN104768540A (zh) 2012-09-05 2015-07-08 才思制药公司 抗胆碱能神经保护组合物和方法
US8716351B1 (en) 2012-12-23 2014-05-06 Liveleaf, Inc. Methods of treating gastrointestinal spasms

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3782107T2 (de) 1986-07-25 1993-04-01 Beecham Group Plc Azabicyclische verbindungen, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
GB8806990D0 (en) 1988-03-23 1988-04-27 Beecham Group Plc Novel compounds
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
EP0306323B1 (en) * 1987-09-03 1994-09-21 Glaxo Group Limited Lactam derivatives
DE3850742T2 (de) 1987-11-04 1994-10-27 Beecham Group Plc Neue 4-Oxobenzotriazine und 4-Oxochinazoline.
US5116984A (en) * 1988-04-07 1992-05-26 Glaxo Group Limited Imidazole derivatives
GB8814277D0 (en) * 1988-06-16 1988-07-20 Glaxo Group Ltd Chemical compounds
US5017573A (en) * 1988-07-29 1991-05-21 Dainippon Pharmaceutical Co., Ltd. Indazole-3-carboxylic acid derivatives
GB8820650D0 (en) 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
GB8823980D0 (en) 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
GB8829079D0 (en) * 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
GB8904551D0 (en) * 1989-02-28 1989-04-12 Glaxo Group Ltd Chemical compounds
EP0387431A1 (en) 1989-03-14 1990-09-19 Beecham Group Plc Imidazole derivatives, process for their preparation and their pharmaceutical use
GB9020927D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Pharmaceuticals
GB9027098D0 (en) * 1990-12-13 1991-02-06 Beecham Group Plc Pharmaceuticals
GB9027487D0 (en) 1990-12-19 1991-02-06 Beecham Group Plc Pharmaceuticals
WO1992012149A1 (en) 1991-01-09 1992-07-23 Smithkline Beecham Plc Azabicydic and azatricydic derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
GB9214184D0 (en) 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
CO5011096A1 (es) 2001-02-28
YU20600A (sh) 2003-10-31
BR9812886A (pt) 2000-08-08
US6284770B1 (en) 2001-09-04
US20010044450A1 (en) 2001-11-22
AU750818B2 (en) 2002-07-25
AU9629398A (en) 1999-04-27
GB9721139D0 (en) 1997-12-03
EA003184B1 (ru) 2003-02-27
KR20010015707A (ko) 2001-02-26
ID23874A (id) 2000-05-25
NO20001776L (no) 2000-06-06
DZ2618A1 (fr) 2003-03-01
IS5425A (is) 2000-03-31
IL135398A0 (en) 2001-05-20
EA200000299A1 (ru) 2000-12-25
AR017296A1 (es) 2001-09-05
PA8461101A1 (es) 2000-05-24
WO1999017755A3 (en) 1999-09-23
NZ503698A (en) 2002-10-25
EE200000214A (et) 2001-06-15
US6593336B2 (en) 2003-07-15
CA2305751A1 (en) 1999-04-15
AP2000001785A0 (en) 2000-06-30
ZA989061B (en) 2001-07-05
PL340337A1 (en) 2001-01-29
US6429209B2 (en) 2002-08-06
HUP0003750A2 (hu) 2001-10-28
SK4862000A3 (en) 2001-01-18
EP1021174A2 (en) 2000-07-26
HRP20000198A2 (en) 2001-04-30
NO20001776D0 (no) 2000-04-06
JP2001518495A (ja) 2001-10-16
TNSN98179A1 (fr) 2005-03-15
US20030036549A1 (en) 2003-02-20
CN1281357A (zh) 2001-01-24
SV1998000122A (es) 1999-07-05
WO1999017755A2 (en) 1999-04-15
MA26549A1 (fr) 2004-12-20
HN1998000155A (es) 1999-05-24
UY25200A1 (es) 2001-01-31
HUP0003750A3 (en) 2003-02-28
PE120299A1 (es) 1999-12-15
GT199800157A (es) 2000-03-30

Similar Documents

Publication Publication Date Title
TR200000913T2 (tr) Tıbbi maddeler
DE69703121D1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
TR200101793T2 (tr) CCR5 modülatörleri olarak azabisikloalkanlar
HUP0103484A2 (hu) Anti-CD20-ellenanyag alkalmazása B-sejtes limfómák kombinációs terápiájára
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
TR199901417T2 (tr) Analjezik etkisi olan yeni bilesimler.
TR200000015T2 (tr) Bileşikler ve metodlar
TR199901172T2 (tr) Yeni ikame edilmis pirazol türevleri.
NO20003550L (no) Farmasøytiske sammensetninger og anvendelse herav
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
BR0215281A (pt) Compostos de succinimida heterocìclicos fundidos e seus análogos, moduladores da função do receptor de hormÈnio nuclear
BR0113980A (pt) Compostos de succinimida heterocìclicos fundidos e seus análogos, moduladores de função de receptor de hormÈnio nuclear
TR199802284T2 (tr) Dopamin D3 reseptörlerinin modülatörleri olarak tetrahidroizokuinolin türevleri.
ATE390917T1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
NO20004419L (no) Ny anvendelse
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
HUP9800938A2 (hu) NK-1 receptor antagonisták alkalmazása irritációs bélszindróma tüneteinek kezelésére
YU13301A (sh) Muskarinski agonisti i antagonisti
DE69711078T2 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
TR200200913T2 (tr) Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları.
NO20005548D0 (no) Mykobakterieinhibitorer
NO20001894L (no) Anvendelse av TNF-antagonister som medikamenter for behandling av septiske sykdommer
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen